Enzastaurin 500 milligram (mg) Once Daily (QD) + Enzastaurin 250 mg Twice Daily (BID)
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Glioblastoma Multiforme
Conditions
Glioblastoma Multiforme
Trial Timeline
Oct 1, 2007 → Mar 1, 2016
NCT ID
NCT00509821About Enzastaurin 500 milligram (mg) Once Daily (QD) + Enzastaurin 250 mg Twice Daily (BID)
Enzastaurin 500 milligram (mg) Once Daily (QD) + Enzastaurin 250 mg Twice Daily (BID) is a phase 2 stage product being developed by Eli Lilly for Glioblastoma Multiforme. The current trial status is completed. This product is registered under clinical trial identifier NCT00509821. Target conditions include Glioblastoma Multiforme.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00509821 | Phase 2 | Completed |
Competing Products
20 competing products in Glioblastoma Multiforme